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Abstract
Background: Ionizing radiation (IR) therapy is a primary treatment for glioblastoma multiforme
(GBM), a common and devastating brain tumor in humans. IR has been shown to induce PI3K-Akt
activation in many cell types, and activation of the PI3K-Akt signaling pathway has been correlated
with radioresistance.
Methods: Initially, the effects of IR on Akt activation were assessed in multiple human GBM cell
lines. Next, to evaluate a potential causative role of IR-induced Akt activation on radiosensitivity,
Akt activation was inhibited during IR with several complementary genetic and pharmacological
approaches, and radiosensitivity measured using clonogenic survival assays.
Results: Three of the eight cell lines tested demonstrated IR-induced Akt activation. Further
studies revealed that IR-induced Akt activation was dependent upon the presence of a serum
factor, and could be inhibited by the EGFR inhibitor AG1478. Inhibition of PI3K activation with
LY294002, or with inducible wild-type PTEN, inhibition of EGFR, as well as direct inhibition of Akt
with two Akt inhibitors during irradiation increased the radiosensitivity of U87MG cells.
Conclusion: These results suggest that Akt may be a central player in a feedback loop whereby
activation of Akt induced by IR increases radioresistance of GBM cells. Targeting the Akt signaling
pathway may have important therapeutic implications when used in combination with IR in the
treatment of a subset of brain tumor patients.
Background
Glioblastoma multiforme (GBM), or grade IV astrocy-
toma, is the most common and lethal primary malignant
brain tumor in humans [1-3]. Despite surgical resection
and treatment with ionizing radiation (IR) and temozola-
mide, the median survival for GBM patients is approxi-
mately 1 year [2,3]. Virtually all patients suffer tumor
recurrence despite aggressive irradiation, emphasizing the
radioresistant nature of GBMs. As such, understanding the
molecular mechanism of radioresistance is essential for
developing more effective radiotherapy treatment regi-
mens for GBM.
The PI3K-Akt signaling pathway is a ubiquitous and evo-
lutionarily conserved signaling cascade that is involved in
numerous cellular functions, including apoptosis, cell
proliferation, differentiation, migration, and metabolism
[4,5]. Activation of PI3K-Akt signaling is associated with
poor prognosis in multiple tumor types, including GBMs
[6,7]. PI3K is coupled with a variety of growth factor-
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dependent receptor tyrosine kinases, such as epidermal
growth factor receptor (EGFR), insulin-like growth factor
receptor, platelet-derived growth factor receptor, and
insulin receptor [8-10]. Upon stimulation of its upstream
receptors, PI3K is activated and generates phosphatidyli-
nositol (3,4,5) P2 (PIP3). PIP3 is converted to inactive
phosphatidylinositol (4,5) P2 (PIP2) by the PTEN lipid
phosphatase, which is commonly deleted or mutated in
GBM [7,11,12].
The most important downstream effector of PI3K signal-
ing is the serine/threonine kinase Akt (also known as
PKB). There are three closely related Akt isoforms in mam-
malian cells, including Akt1 (PKBα), Akt2 (PKBβ), Akt3
(PKBγ) [4]. All Akt isoforms bind to PIP3 through pleck-
strin-homology (PH) domains, and translocate to the
plasma membrane where they are activated via phospho-
rylation at residues Ser473 and Thr308. Once activated,
Akt promotes cellular proliferation and inhibits apoptosis
through phosphorylation of multiple substrates, includ-
ing caspase-9, Bad, GSK3, and forkhead transcription fac-
tors, such as FKHR (FOX1), FKHRL (FOXO3), and AFX
(FOXO4) [5,13].
Activation of PI3K-Akt signaling is important in most
human malignancies, including hematopoietic,
melanoma, non-small cell lung, pancreatic, endometrial
and ovarian, breast, prostate, hepatocellular, and brain
cancers [4,7,11]. PTEN, the primary negative regulator of
the PI3K-Akt signaling pathway, is an important tumor
suppressor. Deletions or inactivating mutations of PTEN
are found in various cancer specimens, cancer cell lines,
and inherited cancer predisposition syndromes, making
PTEN one of the most commonly inactivated tumor sup-
pressor genes in human cancer [12,14]. Recently, muta-
tions in PIK3CA (encoding the catalytic subunit of PI3K,
P110α) were observed in multiple cancers, including
brain tumors, further supporting the fundamental role of
PI3K pathway activation in the pathogenesis of human
cancer [15,16].
PTEN is among the most frequently mutated or deleted
tumor suppressor genes in GBM, as genetic and epigenetic
alterations have been identified in at least 60% of patients
[7]. Importantly, the role of PI3K-Akt signaling in gliom-
agenesis has been demonstrated in both animal and cell
culture models. Activating Akt by deletion of PTEN or by
Myr-Akt (constitutively active Akt) expression has been
shown to increase tumor incidence, accelerate tumor
onset, and elevate tumor malignancy in multiple mouse
glioma models [17,18]. Akt activation is also crucial for
the transformation of human astrocytes in vitro [7,19],
and EGFR, an upstream regulator of PI3K-Akt signaling, is
also commonly activated in GBM [7,16,20].
Activation of the PI3K-Akt signaling pathway is associated
with radioresistance in many cancers, including those of
the colon, bladder, prostate, head and neck, cervix, and
brain [21,22]. Inhibition of the PI3K-Akt pathway has
been shown to impair DNA repair after IR [23,24], and
result in radiosensitization in a variety of different cell
types including human GBMs [22,25] For example, inhi-
bition of PI3K-Akt pathway via treatment with PI3K
inhibitors or PTEN expression has been shown to increase
radiosensitivity in human GBM cells [26,27]. Although
most reports indicate that inhibition of Akt activation
reduces radiosensitivity, a report from del la Pena et al
showed little or no effect of Akt activation on the effective-
ness of IR treatment in a number of human GBM cell lines
[28].
Importantly, IR has been shown to induce Akt activation
in multiple cell types, including some human GBM cells
[29-31]. In this study, we investigated PI3K-Akt activation
following irradiation in multiple GBM cell lines, and
assessed its effect on the ability of human gliobastoma cell
lines to respond to IR treatment. To evaluate the effect of
IR induced Akt activation on radiosensitivity, Akt activa-
tion was inhibited during IR with various genetic and
pharmacological approaches. We found that pharmaco-
logic and genetic inhibition of PI3K activity, as well as
direct pharmacological inhibition of EGFR and Akt led to
increased radiosensitivity of human GBM cells.
Methods
Cell culture and reagents
U87MG, MO59J, LN18, H4, A172, DBTRG-05MG,
LN229, and HS683 cells were obtained from the Ameri-
can Type Culture Collection, and were cultured in Dul-
becco's modified Eagle's medium (Invitrogen)
supplemented with 10% FBS and 1% penicillin/strepto-
mycin. U87MG cells containing transgenes for inducible
wild-type PTEN, or the phosphatase-inactive mutant form
of PTEN, PTEN-C124S, were gifts from Dr. Georgescu
[32], and were grown in Dulbecco's modified Eagle's
medium containing 0.5 mg/mL G418, 10 μg/mL blastici-
din (Invitrogen), 10% FBS, and 1% penicillin/streptomy-
cin. All cells were incubated at 37°C in 5% CO2.
LY294002 and doxycycline were purchased from Sigma,
AG1478 from Biosource, SH-5 from Calbiochem, and
MK-2206 from Selleck Chemicals.
Irradiation
Sub-confluent cell monolayers were irradiated using a J.L.
Shepard Mark I 137Cs irradiator at ~2 Gy/min.
Western blot analysis
Cells were lysed in lysis buffer (Cell Signaling) containing
20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1
mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophos-Radiation Oncology 2009, 4:43 http://www.ro-journal.com/content/4/1/43
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phate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 μg/ml
leupeptin supplemented with proteinase inhibitor cock-
tails (Roche) and phosphatase inhibitor cocktails
(Sigma). Cell lysates were separated by SDS-PAGE and
transferred to PVDF membranes. After probing with pri-
mary antibodies, the membranes were incubated with
horseradish peroxidase-conjugated secondary antibody,
and visualized by ECL (Pierce). Antibodies specific for
total Akt and phospho-Akt (Ser473) were obtained from
Cell Signaling Technologies. Antibodies specific for PTEN
(clone 6H.1) was from Cascade Bioscience, and that for α-
tubulin was from Neomarkers.
Clonogenic Survival Assay
Cells in exponential growth phase were irradiated as
described above. Prior to irradiation, cells were treated
with LY294002, AG1478, SH-5, or doxycycline as
described in the Figure legends. At 4 - 24 hr post-radia-
tion, the cells were detached from the culture dish with
trypsin, and were seeded at various dilutions into 25 cm2
tissue culture flasks in normal medium. Colonies were
allowed to grow for 14 days before staining with a 0.2%
crystal violet/formalin solution, and counted under stere-
omicroscopy. Colonies were defined as clusters of >50
cells. Colony-forming efficiency is reported as the survival
fraction, which is defined as the total number of clones in
irradiated cells divided by total number of clones in oth-
erwise identical unirradiated cells. Each point on the sur-
vival curve represents the mean surviving fraction from at
least three replicates. Cell survival measurements were fit-
ted to a linear quadratic mathematical model using the
GraphPad Prism 4 program [33].
Results
IR induces Akt phosphorylation in a subset of human GBM 
celllines
We began our studies by testing the effect of IR on Akt
phosphorylation in eight GBM cell lines. Akt activation
was assessed by comparing the levels of basal Akt phos-
phorylation to that present 1 hr after a single dose of 6 Gy
radiation. IR led to increased phosphorylation of Akt in
three of the cell lines (U87MG, MO59J, and LN18), which
reached maximal levels within 1 hr of IR treatment, and
maintained an elevated level for several hours (Fig. 1A, B).
From these data we conclude that radiation induces
robust but transient phosphorylation of Akt in a subset of
human GBM cell lines.
IR induces Akt activation in U87MG cells via EGFR in a 
serum factor-dependent manner
U87MG cells, which harbor a mutationally inactivated
PTEN gene by virtue of homozygous splice site mutations
[34], were chosen for subsequent mechanistic and pheno-
typic studies. Initially, we performed a dose response
curve to identify the optimal dose of IR for maximal
induction of Akt phosphorylation. We found that modify-
ing the dose did not enhance Akt phosphorylation (data
not shown).
We next investigated the mechanism of IR-induced Akt
phosphorylation, and began by testing for a serum
requirement for this effect. As shown in Fig. 2A, cells
grown in serum-free conditions displayed attenuated IR-
induced Akt phosphorylation, suggesting that a factor
present in serum is required for optimal IR-induced Akt
phosphorylation.
As EGFR (also known as ErbB1) is commonly activated by
genomic amplification in GBM and has previously been
implicated in radiation resistance [1,9,10,20,35], we
tested if EGFR ligands were the serum factor responsible
for IR-induced Akt phosphorylation. Cells were pretreated
with the EGFR inhibitor AG1478 for 1 hr, and were then
irradiated. Cell lysates were prepared and used in Western
Blot analysis for phosphorylated Akt. As shown in Fig. 2B,
U87MG cells treated with AG1478 failed to undergo IR-
induced Akt activation, indicating that activation of EGFR
by IR is required for IR-induced Akt phosphorylation in
these cells.
Pharmacological inhibition of PI3K and EGFR enhances 
the radiosensitivity of U87MG cells
We next tested if IR-induced Akt signaling modulated the
radiosensitivity of GBM cells. First, a PI3K inhibitor was
used to inhibit IR induced Akt activation, as PI3K is the
upstream signaling molecule for Akt. Cells were pretreated
for 1 hr with LY294002, which is a potent inhibitor of
PI3K, followed by irradiation at 0 - 9 Gy. The cells were
incubated overnight subsequent to removing the drug 4
hr after IR, and their reproductive growth ability was
measured using clonogenic survival assay as described in
the Methods.
As shown in Fig. 3A, LY294002 treatment abolished IR-
induced Akt phosphorylation, indicating that this process
is dependent upon PI3K, which is consistent with other
reports [22]. In addition, treatment with LY294002 signif-
icantly increased the radiosensitivity of U87MG cells (Fig.
3B). For example, 47.1% and 93.0% more cells lost their
ability to form colonies following treatment with 6 Gy
and 9 Gy IR respectively after PI3K was inhibited as
opposed to cells where PI3K signaling remained intact.
These results indicate that inhibition of PI3K signaling
could play an important role in modifying the response of
GBMs to IR treatment, consistent with previous observa-
tions using U251MG cells [27].
As we had previously shown that EGFR activation was
required for IR-induced Akt activation (Fig. 2B), we next
tested to whether EGFR signaling modulated radioresist-Radiation Oncology 2009, 4:43 http://www.ro-journal.com/content/4/1/43
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ance in U87 cells. To do this, we pre-treated U87MG cells
with the EGFR inhibitor AG1478, then treated them with
various doses of IR and performed clonogenic survival
assays. As depicted in Fig. 3C, inhibition of EGFR had the
expected effect of enhancing the radiosensitivity of U87
cells, consistent with its effect on IR-induced Akt activa-
tion.
Genetic inhibition of PI3K signaling enhances the 
radiosensitivity of U87MG cells
In addition to abolishing PI3K activity, LY294002 has
been reported to inhibit other PI3K-like kinases (PIKK),
such as mTOR (mammalian target of rapamycin), DNK
(DNA-dependent protein kinase), and ATM (ataxia telag-
iectasia mutated protein) [36]. These kinases play impor-
The effect of IR on Akt phosphorylation differs in human GBM cell lines Figure 1
The effect of IR on Akt phosphorylation differs in human GBM cell lines. A. U87MG, MO59J and LN18 cells were 
irradiated with 6 Gy and harvested after the indicated times. Cell lysates were prepared and subjected to Western blot analysis 
with the indicated antibody. B. H4, A174, DBTRG-05MG, LN229, and HS683 cells were irradiated with 6 Gy and harvested 
after 1 hr. Cell lysates were prepared and subjected to Western blot analysis with the indicated antibody.Radiation Oncology 2009, 4:43 http://www.ro-journal.com/content/4/1/43
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tant roles in IR-induced DNA damage repair [37-39], and
mTOR regulates the PI3K-Akt signaling pathway at multi-
ple levels [40-43]. As such, it remained possible that the
effect of LY294002 on radiosensitivity was independent of
its effect on PI3K signaling. Therefore, a genetic approach
was used to specifically modulate PI3K-Akt activation and
determine the effect on radiosensitivity.
U87MG cells have mutant PTEN genes [34], leading to a
high level of Akt phosphorylation. To modulate Akt acti-
vation in these cells, genetically modified versions of
U87MG cells harboring tetracycline-inducible wild-type
or mutant PTEN transgenes were studied.
In the absence of doxycycline treatment, both cell lines
expressed little PTEN protein and high levels of phospho-
Akt (Fig. 4A). Treatment for 24 hr with doxycycline
induced robust expression of both wild-type and mutant
PTEN, and only the induction of wild-type PTEN led to a
significant decrease in Akt phosphorylation (Fig. 4A),
confirming that functional PTEN is required for inhibiting
Akt activation in GBM.
Next, these U87MG clones were treated with or without
doxycycline for 24 hr, followed by radiation treatment. 4
hr after IR, the cells were trypsinized and subjected to clo-
nogenic survival assays. As shown in Fig. 4B, expression of
wild-type but not mutant PTEN enhanced the radiosensi-
tivity of U87MG cells. This result is consistent with the
results from LY294002 as well as reports from Jiang et al
[26], and confirms that IR-induced Akt activation contrib-
utes to the radioresistance of U87MG cells.
Pharmacological inhibition of Akt enhances the 
radiosensitivity of U87MG cells
Next, we used Akt inhibitors to directly inhibit IR induced
Akt activation, and assessed the effect on radiosensitivity.
Two different Akt inhibitors, SH-5 and MK-2206 were
tested.
IR induces Akt activation in U87MG cells through EGFR in a serum factor-dependent manner Figure 2
IR induces Akt activation in U87MG cells through EGFR in a serum factor-dependent manner. A. U87MG cells 
were cultured in the absence or presence of 10% FBS for 18-20 hr, then irradiated at 6 Gy. Cell lysates were harvested 1 hr 
later and subjected to Western blot analysis with the indicated antibody. The ratio of P-Akt-Ser473 to total Akt pooled from 
three different experiments were shown in the lower panel. Results represent mean ± SEM, ***:p < 0.001 compared to 0 Gy; 
#: p < 0.05 compared to 10% FBS (one-way ANOVA) B. Cells were treated with 5 μM AG1478 for 1 hr, then were irradiated 
for 1 hr at the indicated dosage. Cell lysates were prepared and subjected to Western blot analysis with the indicated antibody. 
The fold induction of normalized P-Akt-Ser473 induced by 6 Gy pooled from two different experiments were shown in the 
lower panel. Results represent mean ± SEM, **:p < 0.01(Student's t-test).Radiation Oncology 2009, 4:43 http://www.ro-journal.com/content/4/1/43
Page 6 of 10
(page number not for citation purposes)
SH-5 is a structurally modified phosphatidylinositol ether
lipid analogue (PIA) that binds to the PH domain of Akt
[44]. SH-5 has been shown to inhibit Akt activation in
NSCLC H157 cells with IC50~4 μM [44,45]. We found that
overnight incubation with 10 μM SH-5 led to a decrease
in phospho-Akt in U87MG cells. Therefore, U87MG cells
were incubated with 10 μM SH-5 for ~16 hrs, followed by
irradiation at 0 - 9 Gy. SH-5 were removed 4 hr after IR,
and the cells were further incubated overnight, after which
were harvested for clonogenic survival assay as described
in the Methods. As shown in Fig. 5A, SH-5 treatment abol-
ished IR-induced Akt phosphorylation without changing
the total protein levels of Akt. Consistent with this, treat-
ment with SH-5 increased the radiosensitivity of U87MG
cells (Fig. 5-B).
Another tested Akt inhibitor MK-2206 showed similar
effect. MK-2206 is a potent allosteric Akt inhibitor with
IC50 at 8 nm, 2 mM, 65 mM for Akt1, Akt2 and Akt3
respectively [46]. 1 hr treatment of 1 μM MK-2206 abol-
ished Akt phosphorylation in U87MG cells (data not
shown). U87MG cells were preincubated with 1 μM MK-
Inhibition of PI3K-Akt signaling with PI3K inhibitor LY294002 or EGFR inhibitor AG1478 increases the radiosensitivity of  U87MG cells Figure 3
Inhibition of PI3K-Akt signaling with PI3K inhibitor LY294002 or EGFR inhibitor AG1478 increases the radio-
sensitivity of U87MG cells. A. U87MG cells were treated with 20 μM LY294002 for 1 hr prior to IR, and then irradiated 
with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. 
Cells without IR treatment were used as a control. B. Cells were treated with vehicle (control) or 20 μM LY294002 for 1 hr, 
then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 
37°C, after which they were trypsinized and seeded for clonogenic survival assays. Colony-forming efficiency was determined 
14 d later. Results were pooled from three different experiments. C. Cells were treated with vehicle (control) or 5 μM 
AG1478 for 16 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for 
another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency 
was determined 14 d later.Radiation Oncology 2009, 4:43 http://www.ro-journal.com/content/4/1/43
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2206 for 1 hr, followed by irradiation at 0 - 9 Gy. As
shown in Fig 5-C, MK-2206 treatment abolished IR-
induced Akt phosphorylation. Moreover, treatment with
MK-2206 also increased the radiosensitivity of U87MG
cells (Fig. 5-D).
Taken together, these results indicate that Akt is an impor-
tant downstream effector of PI3K signaling in modifying
the response of human GBMs to IR treatment.
Discussion
Our results demonstrate that irradiation leads to activa-
tion of the Akt signaling pathway in a subset of GBM cell
lines. IR-induced Akt activation was dependent upon the
presence of serum factors, and could be inhibited by the
EGFR inhibitor. Inhibiting PI3K, EGFR and Akt activation
during irradiation increased the radiosensitivity of
U87MG cells.
The U87MG cell line is frequently used as a GBM model,
and contains wild-type p53 and mutant PTEN. Our results
show that IR induces Akt activation without changing lev-
els of total Akt. However, this effect is substantially less
robust in serum-free medium. The fact that radiation-
induced Akt activation depends on the presence of serum
factors suggests that activation of growth factor receptors
is involved in this process.
Overexpression of EGFR is one of the most prominent
abnormalities associated with GBMs. Approximately 50%
of GBMs contain over-active EGFR, typically through
EGFR gene amplification or the expression of an active
EGFR mutant. The expression of EGFRvIII, a common
constitutively active EGFR mutant, increases radioresist-
ance in immortalized normal human astrocytes [10].
Clinical studies have also shown that EGFR promotes
resistance to radiation in many tumor types, including
GBMs [10]. Although we did not demonstrate the direct
activation of EGFR by IR in this study, this observation has
been reported by others. For example, Bowers et al
reported that radiation induces EGFR tyrosine phosphor-
ylation in MDA-MB-231 human breast cancer cells min-
utes after irradiation [35]. Considering that the EGFR
inhibitor AG1478 significantly reduced IR-induced Akt
activation, it is conceivable that IR induces PI3K-Akt acti-
vation through EGFR activation.
Increased Akt activation is associated with radiation resist-
ance in various tumor types. However, most experiments
have compared the radiosensitivity of cells with different
Expression of PTEN increases the radiosensitivity of U87MG cells Figure 4
Expression of PTEN increases the radiosensitivity of U87MG cells. A. Genetically modified U87MG cells were treated 
with vehicle or 1 μg/mL doxycycline for 24 hr before harvest. Cell lysates were subjected to Western blot analysis with indi-
cated antibody. B. Genetically modified U87MG cells were treated with 1 μg/mL doxycycline for 24 hr, and then irradiated 
with the indicated does. Afterwards, cells were incubated for 4 hr at 37°C, and trypsinized and seeded for clonogenic assay. 
Colony-forming efficiency was determined 14 d later.Radiation Oncology 2009, 4:43 http://www.ro-journal.com/content/4/1/43
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levels of basal Akt activation [10,47,48]. Since active Akt
promotes cell proliferation and inhibits apoptosis, cells
with elevated basal Akt activation usually have much
higher clone formation efficiency. For example, we found
that in medium containing doxycycline, the plating effi-
ciency was much lower in U87MG cells expressing wild-
type PTEN as opposed to mutant PTEN genes (data not
shown). To account for this difference, our study focused
on the effect of IR-induced Akt activation instead of basal
Akt activation. Therefore, Akt activation was only inhib-
ited by treatment with a drug, or with an inducible
mutant, for a short period of time before and after irradi-
ation, such that Akt activation was not altered during
clone formation and clone formation efficiency remained
constant. Using U87MG cells we showed that inhibiting
IR-induced Akt activation increases radiosensitivity. It is
possible that Akt participates in a feedback loop whereby
activation of Akt induced by IR increases the radioresist-
ance of GBM cells.
Among the eight GBM cell lines tested for Akt activation,
both LN18 and LN229 contain wild-type PTEN, and irra-
diation induced Akt activation in LN18 cells, but not in
LN229 cells. All of the other six GBM cell lines contain
Akt inhibitors increase the radiosensitivity of U87MG cells Figure 5
Akt inhibitors increase the radiosensitivity of U87MG cells. A. U87MG cells were treated with vehicle or 10 μM SH-5 
for 16 hrs, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis 
with the indicated antibody. Cells without IR treatment were used as a control. The relative ratio of P-Akt-Ser473 to total Akt 
pooled from two different experiments are shown in the right panel. Results represent mean ± SEM, ***:p < 0.001 compared 
to vehicle (one-way ANOVA) B. Cells were treated with vehicle (control) or 10 μM SH-5 for 16 hrs, then irradiated with indi-
cated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they 
were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later. C. U87MG 
cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr 
after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control. 
D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, 
cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded 
for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.Radiation Oncology 2009, 4:43 http://www.ro-journal.com/content/4/1/43
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mutant PTEN, but the effects of radiation on Akt activa-
tion were not consistent. Further experiments are needed
to determine if activation of Akt by irradiation is related to
the genetic status of PTEN or other factors critical to this
signaling pathway.
Conclusion
In conclusion, our findings indicate that Akt activation
may have a critical role in radiosensitivity in a subset of
GBM cells. Selective inhibitors that specifically target Akt
signaling may have important therapeutic implications
when used in combination with radiation in the treat-
ment of GBM patients.
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